{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:56:11Z","timestamp":1786571771415,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Natural Science Foundation of Shanghai","award":["23ZR1459500"],"award-info":[{"award-number":["23ZR1459500"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171897"],"award-info":[{"award-number":["82171897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82371923"],"award-info":[{"award-number":["82371923"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To establish a metabolic burden-based clinical-radiological model for predicting postoperative recurrence in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) at Barcelona Clinic Liver Cancer (BCLC) stages 0-A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This retrospective multi-center study included HBV-related HCC (BCLC 0-A) undergoing curative surgery. Metabolic burden was defined as the cumulative number of metabolic abnormalities. Trend test assessed dose-dependent relationship. Predictors were identified via univariate and multivariate Cox regression analyses, and a nomogram was developed. The model underwent internal validation (5-fold, 100 times cross) and external validation. Performance was evaluated using\n                      <jats:italic>C<\/jats:italic>\n                      -index, calibration curves, and decision curve analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The internal and external cohorts consisted of 363 patients (55.9\u2009\u00b1\u200910.7 years, 295 males) and 74 patients (55.5\u2009\u00b1\u200910.2 years, 55 males). Recurrence risk increased by 1.53 times (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.049) and 1.64 times (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018) for patients with 2 and 3\u20134 metabolic abnormalities (\n                      <jats:italic>p<\/jats:italic>\n                      trend\u2009=\u20090.022). Independent predictors included tumor burden score\u2009&gt;\u20092.4 (HR\u2009=\u20092.40,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), metabolic abnormalities\u2009\u2265\u20092 (HR\u2009=\u20091.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023), aspartate transaminase\/alanine transaminase ratio\u2009&gt;\u20091 (HR\u2009=\u20091.51,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012), albumin-bilirubin grade 2 (HR\u2009=\u20091.70,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.020), arterial rim enhancement (HR\u2009=\u20091.87,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) and mosaic appearance (HR\u2009=\u20091.55,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033). C-indices for predicting 2- and 5-year recurrence were 0.728 (95% CI: 0.726\u20130.729) and 0.674 (95% CI: 0.673\u20130.675) in training sets, 0.716 (95% CI: 0.711\u20130.720) and 0.657 (95% CI: 0.653\u20130.660) in internal validation sets, and 0.710 (95% CI: 0.602\u20130.855) and 0.683 (95% CI: 0.594\u20130.798) in external cohort. The model showed higher predictive efficacy (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 for all) and better clinical net benefit compared to BCLC and CNLC staging systems in the very early\/early-stage of HCCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The metabolic burden-based clinical-radiological model effectively predicts postoperative recurrence in HBV-related HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>Patients with HBV-related HCC who have two or more coexisting metabolic abnormalities may have a higher risk of postoperative recurrence. The metabolic burden-based clinical-radiological model is valuable in predicting postoperative recurrence<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Metabolic abnormalities were dose-dependently related to the risk of postoperative recurrence.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The clinical-radiological model showed well-predictive efficacy in validation cohorts.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The clinical-radiological model displayed higher efficacy compared to existing staging systems for the very early\/early-stage of HCCs.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-025-02183-3","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T17:51:48Z","timestamp":1767635508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic burden-based clinical-radiological model for predicting postoperative recurrence of hepatitis B-related hepatocellular carcinoma"],"prefix":"10.1186","volume":"17","author":[{"given":"Beixuan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0450-0932","authenticated-orcid":false,"given":"Mengsu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2183_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2183_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4428-y","volume":"19","author":"H Wang","year":"2019","unstructured":"Wang H, Men P, Xiao Y et al (2019) Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis 19:811. https:\/\/doi.org\/10.1186\/s12879-019-4428-y","journal-title":"BMC Infect Dis"},{"key":"2183_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"key":"2183_CR4","doi-asserted-by":"publisher","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","volume":"29","author":"A Vogel","year":"2018","unstructured":"Vogel A, Cervantes A, Chau I et al (2018) Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv238\u2013iv255. https:\/\/doi.org\/10.1093\/annonc\/mdy308","journal-title":"Ann Oncol"},{"key":"2183_CR5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/bjs.11464","volume":"107","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Moris D, Hyer JM et al (2020) Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 107:854\u2013864. https:\/\/doi.org\/10.1002\/bjs.11464","journal-title":"Br J Surg"},{"key":"2183_CR6","doi-asserted-by":"publisher","first-page":"e0165722","DOI":"10.1371\/journal.pone.0165722","volume":"11","author":"Y Cho","year":"2016","unstructured":"Cho Y, Sinn DH, Yu SJ et al (2016) Survival analysis of single large (> 5 cm) hepatocellular carcinoma patients: BCLC A versus B. PLoS One 11:e0165722. https:\/\/doi.org\/10.1371\/journal.pone.0165722","journal-title":"PLoS One"},{"key":"2183_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sun H, Wang Z et al (2023) Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition). Liver Cancer 12:405\u2013444. https:\/\/doi.org\/10.1159\/000530495","journal-title":"Liver Cancer"},{"key":"2183_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1177\/2050640620904524","volume":"8","author":"S Heinrich","year":"2020","unstructured":"Heinrich S, Sprinzl M, Schmidtmann I et al (2020) Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 8:444\u2013452. https:\/\/doi.org\/10.1177\/2050640620904524","journal-title":"United European Gastroenterol J"},{"key":"2183_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s00268-010-0928-z","volume":"35","author":"WY Kao","year":"2011","unstructured":"Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC (2011) A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg 35:858\u2013867. https:\/\/doi.org\/10.1007\/s00268-010-0928-z","journal-title":"World J Surg"},{"key":"2183_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3348\/kjr.2019.0538","volume":"21","author":"DI Cha","year":"2020","unstructured":"Cha DI, Jang KM, Kim SH, Kim YK, Kim H, Ahn SH (2020) Preoperative prediction for early recurrence can be as accurate as postoperative assessment in single hepatocellular carcinoma patients. Korean J Radiol 21:402\u2013412. https:\/\/doi.org\/10.3348\/kjr.2019.0538","journal-title":"Korean J Radiol"},{"key":"2183_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1148\/radiol.15142394","volume":"276","author":"C An","year":"2015","unstructured":"An C, Kim DW, Park YN, Chung YE, Rhee H, Kim MJ (2015) Single hepatocellular carcinoma: preoperative MR imaging to predict early recurrence after curative resection. Radiology 276:433\u2013443. https:\/\/doi.org\/10.1148\/radiol.15142394","journal-title":"Radiology"},{"key":"2183_CR12","doi-asserted-by":"publisher","unstructured":"Gyamfi J, Kim J, Choi J (2022) Cancer as a metabolic disorder. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23031155","DOI":"10.3390\/ijms23031155"},{"key":"2183_CR13","doi-asserted-by":"publisher","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ (2020) Metabolic reprogramming and cancer progression. Science. https:\/\/doi.org\/10.1126\/science.aaw5473","DOI":"10.1126\/science.aaw5473"},{"key":"2183_CR14","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.cell.2023.01.038","volume":"186","author":"LWS Finley","year":"2023","unstructured":"Finley LWS (2023) What is cancer metabolism?. Cell 186:1670\u20131688. https:\/\/doi.org\/10.1016\/j.cell.2023.01.038","journal-title":"Cell"},{"key":"2183_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41574-022-00773-5","volume":"19","author":"JS Brunner","year":"2023","unstructured":"Brunner JS, Finley LWS (2023) Metabolic determinants of tumour initiation. Nat Rev Endocrinol 19:134\u2013150. https:\/\/doi.org\/10.1038\/s41574-022-00773-5","journal-title":"Nat Rev Endocrinol"},{"key":"2183_CR16","doi-asserted-by":"publisher","unstructured":"Navarro-Ledesma S, Hamed-Hamed D, Gonz\u00e1lez-Mu\u00f1oz A, Pruimboom L (2024) Physical activity, insulin resistance and cancer: a systematic review. Cancers (Basel) 16:656 https:\/\/doi.org\/10.3390\/cancers16030656","DOI":"10.3390\/cancers16030656"},{"key":"2183_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3350\/cmh.2022.0095","volume":"29","author":"T Nakatsuka","year":"2023","unstructured":"Nakatsuka T, Tateishi R (2023) Development and prognosis of hepatocellular carcinoma in patients with diabetes. Clin Mol Hepatol 29:51\u201364. https:\/\/doi.org\/10.3350\/cmh.2022.0095","journal-title":"Clin Mol Hepatol"},{"key":"2183_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/cas.12203","volume":"104","author":"M Kasuga","year":"2013","unstructured":"Kasuga M, Ueki K, Tajima N et al (2013) Report of the Japan Diabetes Society\/Japanese Cancer Association Joint Committee on Diabetes and Cancer. Cancer Sci 104:965\u2013976. https:\/\/doi.org\/10.1111\/cas.12203","journal-title":"Cancer Sci"},{"key":"2183_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","volume":"4","author":"HB El-Serag","year":"2006","unstructured":"El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369\u2013380. https:\/\/doi.org\/10.1016\/j.cgh.2005.12.007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2183_CR20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/hep.29660","volume":"67","author":"TG Simon","year":"2018","unstructured":"Simon TG, King LY, Chong DQ et al (2018) Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology 67:1797\u20131806. https:\/\/doi.org\/10.1002\/hep.29660","journal-title":"Hepatology"},{"key":"2183_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jamaoncol.2018.0035","volume":"4","author":"K Kim","year":"2018","unstructured":"Kim K, Choi S, Park SM (2018) Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a Korean population-based cohort study. JAMA Oncol 4:737\u2013739. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0035","journal-title":"JAMA Oncol"},{"key":"2183_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/hep.24397","volume":"54","author":"TM Welzel","year":"2011","unstructured":"Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA (2011) Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 54:463\u2013471. https:\/\/doi.org\/10.1002\/hep.24397","journal-title":"Hepatology"},{"key":"2183_CR23","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","volume":"17","author":"SC Huang","year":"2023","unstructured":"Huang SC, Su TH, Tseng TC et al (2023) Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int 17:1139\u20131149. https:\/\/doi.org\/10.1007\/s12072-023-10545-6","journal-title":"Hepatol Int"},{"key":"2183_CR24","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1002\/hep.31612","volume":"73","author":"YB Lee","year":"2021","unstructured":"Lee YB, Moon H, Lee JH et al (2021) Association of metabolic risk factors with risks of cancer and all-cause mortality in patients with chronic hepatitis B. Hepatology 73:2266\u20132277. https:\/\/doi.org\/10.1002\/hep.31612","journal-title":"Hepatology"},{"key":"2183_CR25","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1158\/1055-9965.EPI-19-0303","volume":"28","author":"Y Tan","year":"2019","unstructured":"Tan Y, Zhang X, Zhang W et al (2019) The influence of metabolic syndrome on the risk of hepatocellular carcinoma in patients with chronic hepatitis B infection in mainland China. Cancer Epidemiol Biomarkers Prev 28:2038\u20132046. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0303","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2183_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L et al (2020) Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology 71:808\u2013819. https:\/\/doi.org\/10.1002\/hep.31014","journal-title":"Hepatology"},{"key":"2183_CR27","unstructured":"Radiology ACo (2018) Liver imaging reporting and data system version 2018. Available via https:\/\/www.acr.org\/Clinical-Resources\/Clinical-Tools-and-Reference\/Reporting-and-Data-Systems\/LI-RADS. Accessed 17 Jun 2023"},{"key":"2183_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/SLA.0000000000002064","volume":"267","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Morioka D, Conci S et al (2018) The tumor burden score: a new \u201cMetro-ticket\u201d prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 267:132\u2013141. https:\/\/doi.org\/10.1097\/SLA.0000000000002064","journal-title":"Ann Surg"},{"key":"2183_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","volume":"9","author":"XF Pan","year":"2021","unstructured":"Pan XF, Wang L, Pan A (2021) Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol 9:373\u2013392. https:\/\/doi.org\/10.1016\/S2213-8587(21)00045-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2183_CR30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F et al (2020) 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension 75:1334\u20131357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026","journal-title":"Hypertension"},{"key":"2183_CR31","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2023) 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 46:S19\u2013s40. https:\/\/doi.org\/10.2337\/dc23-S002","journal-title":"Diabetes Care"},{"key":"2183_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640\u20131645. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192644","journal-title":"Circulation"},{"key":"2183_CR33","doi-asserted-by":"publisher","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"EL Goode","year":"2017","unstructured":"Goode EL, Block MS, Kalli KR et al (2017) Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 3:e173290. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3290","journal-title":"JAMA Oncol"},{"key":"2183_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1210\/jcem.79.6.7989457","volume":"1","author":"GM Reaven","year":"2005","unstructured":"Reaven GM (2005) Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab 1:9\u201314. https:\/\/doi.org\/10.1210\/jcem.79.6.7989457","journal-title":"Cell Metab"},{"key":"2183_CR35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1152\/physrev.1995.75.3.473","volume":"75","author":"GM Reaven","year":"1995","unstructured":"Reaven GM (1995) Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473\u2013486. https:\/\/doi.org\/10.1152\/physrev.1995.75.3.473","journal-title":"Physiol Rev"},{"key":"2183_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","volume":"16","author":"BD Hopkins","year":"2020","unstructured":"Hopkins BD, Goncalves MD, Cantley LC (2020) Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol 16:276\u2013283. https:\/\/doi.org\/10.1038\/s41574-020-0329-9","journal-title":"Nat Rev Endocrinol"},{"key":"2183_CR37","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1038\/onc.2009.352","volume":"27","author":"S Menon","year":"2008","unstructured":"Menon S, Manning BD (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene 27:S43\u2013S51. https:\/\/doi.org\/10.1038\/onc.2009.352","journal-title":"Oncogene"},{"key":"2183_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-016-0253-6","volume":"9","author":"A You","year":"2016","unstructured":"You A, Cao M, Guo Z et al (2016) Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. J Hematol Oncol 9:20. https:\/\/doi.org\/10.1186\/s13045-016-0253-6","journal-title":"J Hematol Oncol"},{"key":"2183_CR39","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/liv.13280","volume":"37","author":"KM Chan","year":"2017","unstructured":"Chan KM, Kuo CF, Hsu JT et al (2017) Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection. Liver Int 37:434\u2013441. https:\/\/doi.org\/10.1111\/liv.13280","journal-title":"Liver Int"},{"key":"2183_CR40","doi-asserted-by":"publisher","first-page":"102300","DOI":"10.1016\/j.eclinm.2023.102300","volume":"65","author":"D Jeon","year":"2023","unstructured":"Jeon D, Cha HR, Chung SW et al (2023) Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study. EClinicalMedicine 65:102300. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102300","journal-title":"EClinicalMedicine"},{"key":"2183_CR41","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/MEG.0000000000001618","volume":"32","author":"L Geng","year":"2020","unstructured":"Geng L, Zong R, Shi Y, Xu K (2020) Prognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 32:769\u2013778. https:\/\/doi.org\/10.1097\/MEG.0000000000001618","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2183_CR42","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/jvh.13606","volume":"28","author":"J Shen","year":"2021","unstructured":"Shen J, Dai J, Zhang Y et al (2021) Baseline HBV-DNA load plus AST\/ALT ratio predicts prognosis of HBV-related hepatocellular carcinoma after hepatectomy: a multicentre study. J Viral Hepat 28:1587\u20131596. https:\/\/doi.org\/10.1111\/jvh.13606","journal-title":"J Viral Hepat"},{"key":"2183_CR43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1148\/radiol.2021204352","volume":"300","author":"HJ Kang","year":"2021","unstructured":"Kang HJ, Kim H, Lee DH et al (2021) Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology 300:572\u2013582. https:\/\/doi.org\/10.1148\/radiol.2021204352","journal-title":"Radiology"},{"key":"2183_CR44","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Ziol M, Paradis V, Zucman-Rossi J (2019) Molecular and histological correlations in liver cancer. J Hepatol 71:616\u2013630. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.001","journal-title":"J Hepatol"},{"key":"2183_CR45","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.crad.2022.05.018","volume":"77","author":"X Liang","year":"2022","unstructured":"Liang X, Shi S, Gao T (2022) Preoperative gadoxetic acid-enhanced MRI predicts aggressive pathological features in LI-RADS category 5 hepatocellular carcinoma. Clin Radiol 77:708\u2013716. https:\/\/doi.org\/10.1016\/j.crad.2022.05.018","journal-title":"Clin Radiol"},{"key":"2183_CR46","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1007\/s00330-023-09484-5","volume":"33","author":"L Wang","year":"2023","unstructured":"Wang L, Feng B, Li D et al (2023) Risk stratification of solitary hepatocellular carcinoma\u2009\u2264\u20095 cm without microvascular invasion: prognostic values of MR imaging features based on LI-RADS and clinical parameters. Eur Radiol 33:3592\u20133603. https:\/\/doi.org\/10.1007\/s00330-023-09484-5","journal-title":"Eur Radiol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-025-02183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-025-02183-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-025-02183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:03:06Z","timestamp":1767679386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-025-02183-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2183"],"URL":"https:\/\/doi.org\/10.1186\/s13244-025-02183-3","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Zhongshan Hospital, Fudan University (approval no. B2024-240R).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"5"}}